Thursday, January 18, 2018 -- (MedPage Today) -- Meta-analysis compares three classes of treatment head to head
Wednesday, January 17, 2018 -- Case report: After initiation of ledipasvir-sofosbuvir, HCV RNA decreased, and skin lesions improved
Wednesday, January 17, 2018 -- NewsResults from the CLARITY study show Cosentyx (secukinumab) was significantly more effective than Stelara (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks.Contributed Author: Novartis Pharmaceuticals CorporationTopics: Drug Development
Tuesday, January 16, 2018 -- Fresh data support Cosentyx's superiority to Stelara in treating plaque psoriasis.
Tuesday, January 16, 2018 -- Novartis has released trial data showing that Cosentyx was “significantly more effective” than Johnson & Johnson’s rival biologic Stelara in achieving clear skin in patients with psoriasis.
Friday, January 12, 2018 -- But obesity (MedPage Today) -- with or without psoriasis -- ups pediatric risks even more
Thursday, January 11, 2018 -- Those with psoriasis at higher risk for diabetes, liver disease, elevated lipid levels independent of obesity
Wednesday, December 20, 2017 -- Treatment with biologic agents in psoriasis may reduce risk of depressive symptoms.
Sunday, December 17, 2017 -- (MedPage Today) -- Experts make case for spectrum concept in dermal inflammation
Wednesday, December 13, 2017 -- WILMINGTON, Del., Dec. 13, 2017 -- Allay Rx, a subsidiary of Amalgam Rx, Inc., a leading digital therapeutics company, announced today a partnership on a comprehensive behavioral and patient support program, BEYOND, for...
Monday, December 11, 2017 -- Smoking is positively associated with the risk for PsA in the general population, but negatively associated with PsA in patients with psoriasis.
Wednesday, December 06, 2017 -- Medication-related adverse events occur more frequently with methotrexate in children with moderate to severe psoriasis.
Wednesday, December 06, 2017 -- The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way, one analyst says.
Tuesday, December 05, 2017 -- AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators. An interleukin-23 inhibitor, risankizumab is one of a group of new drugs that AbbVie hopes...
Monday, December 04, 2017 -- By Dr. Mercola For people who don't have it, psoriasis may seem like a minor condition that may be slightly unsightly and mildly irritating. In reality, however, this can be a long-term skin condition, evidenced by patches of skin anywhere on your body that can be not just scaly and irritated but swollen and painful. It can also lead to other, more serious problems. Today, about 7.5 million people in the U.S. suffer from this chronic condition, caused by cell buildup that is not just on the surface but goes deeper, often bringing joint pain from psoriatic arthritis. Further, asthma, diabetes, heart disease and even depression have been traced back to psoriasis. Conventional treatments for psoriasis, depending on the
Sunday, December 03, 2017 -- People with psoriasis may notice that their symptoms tend to get better in the summer, when they are more exposed to the sun. Does sunlight heal psoriasis?
Saturday, December 02, 2017 -- In mouse models of psoriasis, researchers found that oral administration of a synthetic vanilla extract called vanillin reduced skin inflammation.
Friday, December 01, 2017 -- Impoyz Cream will be available as a 0.025% cream in 60g and 112g tubes.
Thursday, November 30, 2017 -- BEVERLY, Mass., Nov. 30, 2017 -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that the last patient has completed study treatment in the...
Thursday, November 30, 2017 -- Novartis says Cosentyx is the first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90 percent of psoriasis patients.